Nine Biotech Companies that Could Revolutionize Obesity Treatments

Why It Matters

The surge in obesity‑focused biotech pipelines promises broader therapeutic options and intensifies competition, potentially lowering costs and expanding access for patients worldwide.

Key Takeaways

• GLP‑1 agonists dominate pipeline across nine firms
• Several candidates show >14% weight loss in early trials
• Funding exceeds $5 billion for obesity biotech development
• Oral GLP‑1 formulations aim to improve patient adherence
• Market projected $150 billion by 2035, reshaping pharma

Pulse Analysis

The global obesity epidemic has turned metabolic disease into a top priority for investors and regulators alike. While injectable GLP‑1 agonists like Wegovy and Zepbound have demonstrated blockbuster revenues, their administration burden and cost have spurred a wave of innovation. Biotech companies are now exploring dual‑agonist peptides, GIP antagonists, and oral delivery platforms to enhance efficacy, safety, and patient convenience, positioning themselves to capture a share of the rapidly expanding market.

Among the nine highlighted firms, several standouts are reshaping the therapeutic landscape. Zealand Pharma’s dual‑agonist Survodutide achieved up to 19% weight loss in Phase 2, while Viking Therapeutics’ VK2735 posted 14.7% loss in just 13 weeks, earning a green light for Phase 3. Structure Therapeutics is pioneering oral incretin therapy with aleniglipron, and Verdiva Bio’s VRB‑101 aims to deliver GLP‑1 orally. Collectively, these companies have secured more than $5 billion in capital, underscoring the confidence of venture and public markets in next‑generation obesity solutions.

The competitive pressure on established players is intensifying, with the projected $150 billion market by 2035 promising substantial upside for successful entrants. Oral formulations and multi‑agonist strategies could lower barriers to adoption, driving broader patient uptake and potentially reshaping pricing dynamics. For investors, the diversification of mechanisms and the progression of multiple candidates into Phase 3 and Phase 4 trials signal a fertile environment for value creation, while clinicians anticipate a richer arsenal to combat obesity and its associated comorbidities.